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Risk of Surgical Hemorrhage
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Abstract
Background: Withdrawal of oral antiplatelet therapy (OAT) is a major risk factor for stent thrombosis, myo-
cardial infarction, and cerebral strokes. In order to minimize the risk for thrombotic complications, since 2007
robotic-assisted laparoscopic radical prostatectomy (RARP) has taken place under continuous OAT with aspirin
at our institution. In this retrospective study we analyzed the risk for perioperative bleeding and surgical
outcome after RARP with OAT.
Patients and Methods: All patients who underwent RARP with aspirin OAT at our institution since 2007 were
included in this analysis. The OAT group was compared with a group that underwent RARP without OAT,
which contained twice the number of patients. Matching of the two groups was performed with regard to the
tumor stage and whether a lymph node dissection or nerve-sparing was performed.
Results: Thirty-eight patients were assigned to the OAT group and 76 to the control group. A difference in the
decrease of postoperative hemoglobin concentration was not detectable between the two groups (mean drop of
2.9 – 1.4 g/dL and 2.9 – 1.1 g/dL, respectively; P = .93). RARP was completed in all OAT patients without con-
version to open surgery. Two of the 38 patients (5.3%) in the OAT group and none in the control group required
blood transfusions (P= .11). Equivalent rates of positive surgical margins for pT2 tumors were detected (16%
OAT versus 14% control group; P = 1.0). No adverse cardiovascular events occurred in either group during the
hospitalization.
Conclusions: Continued perioperative OAT with aspirin in RARP is safe, feasible, and not associated with
increased blood loss.
Introduction
The number of patients with cerebrovascular or coro-nary heart disease is growing, and the use of coronary
stents and antiplatelet drugs is increasing.1 Accordingly, in-
creasing numbers of patients presenting for surgery are trea-
ted with antiplatelet medication. Five percent of patients
receiving an intracoronary stent will undergo noncardiac
surgerywithin the first year after intervention.2 Depending on
the type of stent, patients may require single or dual oral
antiplatelet therapy (OAT) for a certain time period, either
with aspirin (acetylsalicylic acid) alone (montherapy) or in
combination with a second antiplatelet agent, most com-
monly an ADP receptor antagonist such as clopidogrel (dual
therapy). The current guidelines recommend 1 month of dual
antiplatelet therapy after a bare-metal coronary stent and 1
year of dual antiplatelet therapy after a drug-eluting coronary
stent.3 Lifelong continuation of aspirin after this time period is
highly recommended.4 Other indications for a lifelong sec-
ondary prophylaxis (preventing the recurrence of the disease)
with aspirin are stroke, angina pectoris, myocardial infarc-
tion, or endovascular/open revascularization.4
The interruption of OAT during invasive, noncardiac pro-
cedures in patients with coronary stents is associated with a
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high risk of cardiovascular complications.5–7 Despite this,
perioperative withdrawal of antiplatelet therapy is still widely
practiced. Urologists often tend to discontinue the antiplatelet
therapy because of concerns of increased intraoperative or
postoperative bleeding complications.8 Nevertheless, thrombo-
embolic complications such as myocardial infarction and cere-
bral strokes are often irreversible and have a significant
morbidity and mortality.5
Radical prostatectomy is an elective surgical procedure
with the potential for significant blood loss.9 Therefore, cur-
rent recommendations suggest postponing radical prostatec-
tomy whenever possible and performing it later without any
type of OAT or choosing a noninvasive therapy.10 However,
the increased blood loss due to OAT with aspirin may be
minimized by using a minimally invasive (laparoscopic),
meticulous surgical technique and may be compensated for
by intense postoperative monitoring and transfusions if nec-
essary. Robotic-assisted laparoscopic radical prostatectomy
(RARP) has been performed under continuousOATwith low-
dose aspirin for secondary prevention at our institution since
2007 to minimize the risk of fatal thromboembolic complica-
tions. In this retrospective investigation, we analyzed the risk
for perioperative bleeding and assessed the surgical outcome
after RARP performed with continued OAT.
Patients and Methods
Patient selection and matching
A retrospective electronic chart review of patients at our
institution from March 2007 to October 2012 identified all pa-
tients who underwent RARP under continuousOATwith low-
dose aspirin (100mg/day) (OAT group). Documentation of
continued OAT before admission and intake of aspirin on the
day of surgery were required criteria for inclusion in the OAT
group. Patients taking other antiplatelet agents were excluded.
This group was compared with a double-sized, randomly
matched sample of RARP patients without OAT (the control
group). Matching of the two groups was performed with re-
gards to tumor stage (pT) andwhether a lymphnodedissection
or nerve-sparing was performed. Approval for this retrospec-
tive study was given by the Internal Review Board (protocol
number USZ-917).
Surgical technique
RARPs were performed using the four-arm daVinci Sur-
gical System (Intuitive Surgical Inc., Sunnyvale, CA) by a
transperitoneal approach. Indications for the bilateral ex-
tended pelvic lymph node dissection (EPLND) were either a
prostate-specific antigen level of q10 ng/mL or a preopera-
tive Gleason score ofq7. Boundaries of the EPLND have been
described previously.11 After identification of important
landmarks, the lymphatics covering the external iliac vein, the
obturator lymphatic packet, and the lymphatics overlying the
internal iliac artery were removed on both sides.
Once the EPLNDwas completed, the extraperitoneal space
was entered through lateral mobilization of the bladder, and
an incision of the endopelvic fascia wasmade to gain access to
the lateral surface of the prostate. After preparation of the
ventral part of the prostate, ligation of the Santorini plexus
was performed. Following dissection of the bladder neck in a
straight line down to the pillars (antegrade approach), the
seminal vesicles were removed completely, and the dorsal
surface of the prostate was released. In the case of a nerve-
sparing approach, the preparation of the neurovascular bundle
was performed with clips and without coagulation to avoid
thermal damage to the nerve fibers. After careful preparation of
the apex, the prostatewas removed.A posteriormusculofascial
plate reconstruction according to Rocco et al.12 was completed,
and finally the vesicourethral anastomosiswas performedwith
running or interrupted sutures. On postoperative Day 5,
cystography was performed, and the urinary catheter was
removed if no vesicourethral leak was detected.
Data collection
A retrospective analysis of electronic patient charts was
performed. The following data were collected: age, body mass
index, preoperative prostate-specific antigen level, clinical
stage (cT), biopsy Gleason score, preoperative physical state
assessed by the American Society of Anesthesiologists physical
status classification system (ASA), operation time, accom-
plishment of EPLND and nerve-sparing, pathologic Gleason
score, tumor stage (pT), nodal and margin status, lymph node
yield, weight of prostate specimen, presence of anastomotic
leakage, day of catheter removal, duration of hospital stay, and
postoperative complications. To assess bleeding, we recorded
the estimated blood loss, the hemoglobin/thrombocyte levels
before and after surgery, and the need for blood transfusions
(red blood cells, fresh frozen plasma, or thrombocytes), with
the number of administered units. Postoperative complications
were graded according to the Clavien–Dindo classification.13
Blood count and pathological evaluation
Total blood count, including hemoglobin and thrombo-
cytes, was routinely performed preoperatively and on the first
day after surgery. For further analysis of the hemoglobin and
thrombocyte course, themedian dropwas chosen as the cutoff
value (2.9 g/dL and 54· 103 platelets/lL). The pathological
tumor stage, Gleason score, surgical margin, and lymph node
status were retrieved from the pathology report of the In-
stitute of Clinical Pathology of the University Hospital Zu¨rich.
Detailed comprehensive pathologic analysis was performed
using standardized whole-mount sections. If tumor cells were
detectable at the inked surface, the surgical margins were
considered positive.14
Statistical analysis
PASW version 18.0 (SPSS Inc., Chicago, IL) was used for
statistical analyses. The OAT group and the control group
were compared using Fisher’s exact test for categorical vari-
ables and the Mann–Whitney U test for continuous variables.
All P values are two-sided and are considered significant for
Pp.05.
Results
Descriptive analysis
In total, 114 patients were included in this analysis. Thirty-
eight patients received an RARP with continued OAT (100mg
of aspirin/day). All but 2 of the patients received aspirin
for secondary prophylaxis after cardiac or cerebrovascular
events. These 2 patients received aspirin for idiopathic
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thrombocythemia or for primary prophylaxis. Matching of the
two groups resulted in comparable preoperative baseline
parameters except for different rates in ASA grading (Table 1):
the percentage of patients classified asASA IIIwas significantly
higher in the OAT group compared with the control group
(15.8% versus 4.3%; P= 0.001).
Intraoperative parameters are presented in Table 2. EPLND
was performed in 84.2% of cases, and nerve-sparing was
performed in 42.1% of cases (matched variables). The mean
operation time was comparable between the two groups
(229 – 55 minutes versus 253 – 58 minutes, P = .15). RARP was
completed in all OAT patients without conversion to open
surgery. In 1 patient from the control group, the operation
was converted to open prostatectomy because of extensive
intra-abdominal adhesions after a previous abdominal
surgery. No significant difference in the estimated intra-
operative blood loss (271 – 172mL in the OAT group versus
345 – 282mL in the control group; P = 0.21), decrease of he-
moglobin levels ( - 2.9 – 1.4 g/dL versus - 2.9 – 1.1 g/dL;
P = 0.93), or decrease of thrombocyte levels (- 47– 90· 103/lL
versus - 55 – 30 · 103/lL; P = .70) could be observed.
The postoperative results are presented in Table 3. No
significant differences were detectable between the two
groups. Two patients in the OAT group, both taking aspirin
because of coronary heart disease and coronary stenting, re-
ceived blood transfusions postoperatively. One of these pa-
tients received 2 units of packed red blood cells on the first
postoperative day; this patient had a hemoglobin level of
6.4 g/dL and was in a hemodynamically stable condition.
Clinically, no source of bleeding could be detected, but be-
cause of a postoperative international normalized ratio (INR)
of 2.0 (preoperatively 1.0), 1 unit of fresh frozen plasma and
intravenous vitamin K were administered. A sufficient in-
crease of the hemoglobin level was achieved (9.5 g/dL on the
second postoperative day), and no further transfusion was
necessary. The other of these 2 patients received 1 unit of
packed red blood cells on the first postoperative day; this
patient had a hemoglobin level of 8.0 g/dL (preoperatively
13.6 g/dL) and complained of dizziness. A second unit was
administered on the second postoperative day because of a
further decrease of the hemoglobin level to 7.5 g/dL. The
dizziness improved quickly, and the hemoglobin level in-
creased to 9.5 g/dL. Again, clinically, no source of bleeding
could be detected. In the control group, no patient received
Table 1. Preoperative Data
OAT group
(n = 38)
Control
(n = 76) P
Age (years) 64.6 – 5.7 63.6 (– 6.8) .55
Body mass index (kg/m2) 27.6 – 4.1 26.4 – 3.2 .21
Clinical stage
pT1 26 (68.4%) 47 (61.8%) .27
pT2 10 (26.3%) 28 (36.8%)
pT3b 2 (5.3%) 1 (1.3%)
Preoperative PSA (ng/mL) 7.0 – 3.0 9.8 – 8.0 .08
Gleason biopsy score
5–6 8 (21.1%) 19 (25%) .75
7 20 (52.6%) 42 (55.3%)
8–10 10 (26.3%) 15 (19.7%)
ASA physical status classification
I 0 (0%) 18 (26.1%) < .001a
II 32 (84.2%) 48 (69.6%)
III 6 (15.8%) 3 (4.3%)
Data are mean– standard deviation values or number (%).
aP values p.05 indicate a significant difference.
ASA, American Society of Anesthesiologists; OAT, oral antiplate-
let therapy; PSA, prostate-specific antigen.
Table 2. Intraoperative Data
OAT group
(n = 38)
Control
(n = 76) P
Operation time
(minutes)
229– 55 253– 58 .15
Estimated blood loss (mL) 271 – 172 345 – 282 .21
Lymph node dissection 32 (84.2%) 64 (84.2%) 1.00
Lymph node yield 19.4 – 8.8 19.8 – 9.1 .90
Positive nodal status 1 (3.1%) 7 (10.9%) .26
Nerve-sparing
None 22 (57.9%) 44 (57.9%) 1.00
One side 11 (28.9%) 22 (28.9%)
Both sides 5 (13.2%) 10 (13.2%)
Hemoglobin (g/dL)
Preoperative 14.7 (0.9) 14.9 – 0.9 .33
Postoperative 11.8 – 1.4 12.0 – 1.1 .63
Difference - 2.9 – 1.4 - 2.9 – 1.1 .93
Hemoglobin difference
< 2.9 g/dL 15 (39.5%) 40 (52.6%) .23
q2.9 g/dL 23 (60.5%) 36 (47.4%)
Thrombocytes (103/lL)
Preoperative 257.3– 89.5 251.7– 54.0 .53
Postoperative 213.74– 148.7 196.8– 44.6 .56
Difference - 47.1 – 90.4 - 55.8 – 30.0 .70
Thrombocyte difference
< 54 103/lL 17 (50%) 32 (43.2%) .53
q54 103/lL 17 (50%) 42 (56.8%)
Data are mean– standard deviation values or number (%).
OAT, oral antiplatelet therapy.
Table 3. Postoperative Data
OAT group
(n = 38)
Control
(n = 76) P
Transfusion rate
Red blood cells 2 (5.3%) 0 (0%) .11
Fresh frozen plasma 1 (2.6%) 0 (0%) .33
Thrombocytes 0 (0%) 0 (0%)
Gleason score
5–6 4 (10.5%) 10 (13.2%) .77
7 23 (60.5%) 49 (64.5%)
8–10 11 (28.9%) 17 (22.4%)
Pathologic stage
pT2a-c 25 (65.8%) 50 (65.8%) 1.00
pT3ab 13 (34.2%) 26 (34.2%)
Positive margin status
pT2a-c 4 (16%) 7 (14%) 1.00
pT3ab 8 (61.5%) 12 (46.2%) .50
Weight of prostate (g) 50.4 – 19.4 51.5 – 16.5 .54
Anastomotic leak 4 (10.5%) 8 (10.5%) 1.00
Catheter removal day (days) 6 – 3 9 – 10 .47
Hospital stay (days) 8 – 3 9– 5 .19
Data are mean – standard deviation values or number (%).
OAT, oral antiplatelet therapy.
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blood transfusions. No further bleeding complications arose
in the entire cohort. No patient developed adverse cardiovas-
cular events intra- or postoperatively during hospitalization.
Only minor complications (Clavien–Dindo grade I–II) oc-
curred in the OAT group (Table 4). Anastomotic leakage rates
(10.5% versus 10.5%; P = 1.00) and total complication rates
(21.1% versus 21.4%; P = 1.00) were equal with a mean hos-
pitalization time of 8 days in both groups (8– 3 days and 8– 5
days; P = .19).
Pathologic evaluation
Evaluation of the collected specimens revealed that 65.8%
of the patients had a pT2 tumor (matched variable; see Table
3). No significant difference in the distribution of the Gleason
scores was observed (P= .77). The rate of positive surgical
margins for localized tumors (pT2)was comparable in the two
groups (16% versus 14%; P = 1.0). For pT3 tumors, the rate for
positive surgical margins was 61.5% in the OAT group and
46.2% in the control group (P = .50).
Discussion
For a long time, it has been an accepted policy to stop anti-
platelet treatment 7–10 days before surgery to avoid bleeding
complications. Currently, it is known that this policy puts
patients at an increased risk for thromboembolic events
compared with patients with ongoing OAT during the oper-
ation.5 The withdrawal of antiplatelet drugs generally results
in a very high risk of major cerebro- and cardiovascular
complications, such as myocardial infarction, stent thrombo-
sis, and cerebral strokes, with amortality rate of up to 45%.4,15
The American Heart Association recommends dual anti-
platelet therapy for the first 12 months following drug-eluting
stent insertion.6 Afterward, a lifelong continuation of low-
dose aspirin for secondary prevention is recommended. In a
meta-analysis performed by the Antithrombotic Trialists’
Collaboration, secondary prevention with aspirin resulted in
a 30% decrease of the myocardial re-infarction rate and a 25%
decrease of the stroke rate.16 OATwithdrawal not only results
in the restoration of thrombocyte function, but also induces a
rebound hypercoagulability with prothrombotic effects over-
coming the physiological balance.17,18 In a meta-analysis of
50,279 patients with OAT for the secondary prevention of cor-
onaryheartdisease, theaveragedelaybetweenstoppingaspirin
and thrombotic events was 8.5 days.19 This delay encompasses
most of the time frame relevant to surgical procedures and
thereby further increases the risk of intra- or perioperative
cardiovascular events. Simultaneously, it is well known that
surgical interventions promote thrombosis by increasing the
synthesis of procoagulant clotting factors.4 In a recently per-
formed observational multicenter studywith 1134 patients, the
preoperative discontinuation of OAT for more than 5 days was
an independent prognostic factor formajor adverse cardiac and
cerebrovascular events (odds ratio2.11, 95%confidence interval
1.23–3.63; P= .007); however, continuation of OAT was not
identified as a risk factor for major bleeding.5
Several investigations have reported an increased blood
loss in noncardiac surgery of between 2.5% and 20% for pa-
tients who receive aspirin during the perioperative period.4 It
is notable that, except during intracranial surgery, no increase
in surgical mortality and morbidity was observed. This is a
key factor in weighing the consequences of aspirin continua-
tion or withdrawal. Therefore, on the basis of the present
evidence, although most trials regarding this issue have been
observational and retrospective, perioperative continuation of
aspirin has become increasingly supported in different med-
ical fields.4,20
Previously, a retrospective analysis of patients undergoing
open radical retropubic prostatectomy in 1990 detected a
higher risk for bleeding in 52 aspirin-treated patients.21 Be-
cause of ambiguous data about the safety of transurethral
resection of the prostate (conventional electroresection), the
recommendations for prostate surgery do not provide definite
advice.10,22,23 Considering the reports on blood loss in non-
OAT patients, laparoscopic radical prostatectomy and RARP
seemed to be promising techniques for the reduction of
hemorrhagic complications. Although blood loss for radical
retropubic prostatectomy ranged from 750 to 1284mL, the
Table 4. Complications According to the Clavien–Dindo Classification
Clavien
OAT group
(n = 38)
Control
(n = 76) Details
Grade I 4 (10.5%) 14 (18.4%) OAT group: 4 prolonged catheterizations
(3 leakages, 1 urinary retention)
Control group: 1 lymphocele, 1 reversible peripheral
neurologic symptoms, 1 bedside wound opening, 11 prolonged
catheterizations (7 leakages, 4 urinary retentions)
Grade II 4 (10.5%) 2 (2.6%) OAT group: 1 paralytic ileus, 2 blood transfusions,
1 deep vein thrombosis
Control group: 1 epididymitis, 1 SIRS with unknown focus
Grade III
Grade IIIa 0 0
Grade IIIb 0 1 (1.3%) Control group: 1 urinoma requiring
surgical intervention
Grade IV
Grade IVa 0 0
Grade IVb 0 0
Grade V 0 0
Total 8 (21.1 %) 17 (21.4%) P = 1.00
OAT, oral antiplatelet therapy; SIRS, systemic inflammatory response syndrome.
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blood loss for laparoscopic radical prostatectomy was signi-
ficantly reduced, ranging from 200 to 390mL.9 RARP again
resulted in a slight but further decrease in blood loss, ranging
from 50mL to 273mL.9,24 Along with this development, sig-
nificantly lower transfusion rates were reported.9 Possible
explanations for this reduction are the increased intra-
abdominal pressure in minimally invasive approaches and,
particularly in RARP, a combination of improved visualiza-
tion and more intuitive handling of surgical instruments,
leading to more precise preparation.
Recently, Nowfar et al.25 presented the first study showing
that RARP with aspirin therapy is feasible and not associated
with an increased transfusion rate (0%). However, the OAT
group in this study consisted of only 6 patients, limiting its
statistical power and the conclusion. Subsequently, Parikh
et al.26 and Binhas et al.27 presented their first data with larger
cohorts regarding the implementation of laparoscopic radical
prostatectomy/RARP under continuous OAT. They reported
no significant differences in the transfusion rates and post-
operative hemorrhagic complications. However, both studies
reported significant differences in the preoperative para-
meters due to the lack of randomization or matching. Further-
more, no data on the oncological and early surgical outcome26
or on the oncological outcome only27 were presented.
To achieve comparable groups, we performed a matching
of patients according to tumor stage, nerve-sparing, and
lymphadenectomy. Each of these factors may have an inde-
pendent influence on surgical margins or blood loss. Because
of this matching, the preoperative parameters were equal or
comparable.
In the present investigation, we have shown that RARP
with low-dose aspirin therapy is feasible and safe. No major
bleeding complications occurred intraoperatively, no proce-
dures were converted to open surgery, and no patient in the
OAT group required any type of postoperative invasive in-
tervention (Clavien–Dindo classification grade III or higher).
Two patients (5.3%) received blood transfusions, although
both were hemodynamically stable. Furthermore, no limita-
tions regarding tumor control (surgical margins, lymph node
yield) or early surgical outcome (anastomotic leakage) were
observed. Most important is that despite a high proportion of
ASA III patients in the OAT group, no cardiovascular events
occurred during the postoperative period.
The limitations of this analysis are its retrospective nature
and, therefore, its lack of randomization. Without defined
transfusion thresholds, a more liberal transfusion strategy in
patientswithpreexistingcardiovasculardiseasecannotberuled
out. Additionally, because the surgeon was aware of the con-
tinued OAT, his decisions about the dissection and his estima-
tion of the blood lossmight have been influenced.However,we
have nevertheless demonstrated a comparable outcome with-
out a loss of clinical safety in RARP under continued OAT.
Conclusions
In general, the high risks and consequences of cardiovascular
events after the withdrawal of antiplatelet drugs for secondary
prevention outweigh the risk of intra- and postoperative bleed-
ing due to continued antiplatelet treatment. Patients requiring
antiplatelet therapy should therefore be evaluated individually
and discussed with cardiologists and anesthesiologists before
this vital prophylaxis is withdrawn prior to surgery.
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